163 related articles for article (PubMed ID: 38011437)
1. Association of helicobacter pylori with multiple sclerosis: Protective or risk factor?
Mirmosayyeb O; Barzegar M; Nehzat N; Najdaghi S; Ansari B; Shaygannejad V
Curr J Neurol; 2020 Apr; 19(2):59-66. PubMed ID: 38011437
[No Abstract] [Full Text] [Related]
2. Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis.
Efthymiou G; Dardiotis E; Liaskos C; Marou E; Tsimourtou V; Rigopoulou EI; Scheper T; Daponte A; Meyer W; Sakkas LI; Hadjigeorgiou G; Bogdanos DP
Sci Rep; 2017 Aug; 7(1):7929. PubMed ID: 28801580
[TBL] [Abstract][Full Text] [Related]
3. Relation of helicobacter pylori infection and multiple sclerosis in Iranian patients.
Mohebi N; Mamarabadi M; Moghaddasi M
Neurol Int; 2013 Jun; 5(2):31-3. PubMed ID: 23888213
[TBL] [Abstract][Full Text] [Related]
4.
Malli C; Pandit L; D'Cunha A; Sudhir A
Front Immunol; 2023; 14():1162248. PubMed ID: 37304259
[TBL] [Abstract][Full Text] [Related]
5. The protective effect of Helicobacter Pylori infection on the susceptibility of multiple sclerosis.
Ranjbar R; Karampoor S; Jalilian FA
J Neuroimmunol; 2019 Dec; 337():577069. PubMed ID: 31610314
[TBL] [Abstract][Full Text] [Related]
6. Relevance of
Gerges SE; Alosh TK; Khalil SH; El Din MMW
Egypt J Neurol Psychiatr Neurosurg; 2018; 54(1):41. PubMed ID: 30595647
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori infection is identified as a cardiovascular risk factor in Central Africans.
Longo-Mbenza B; Nsenga JN; Mokondjimobe E; Gombet T; Assori IN; Ibara JR; Ellenga-Mbolla B; Vangu DN; Fuele SM
Vasc Health Risk Manag; 2012; 6():455-61. PubMed ID: 22923995
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
10. Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica.
Li W; Minohara M; Piao H; Matsushita T; Masaki K; Matsuoka T; Isobe N; Su JJ; Ohyagi Y; Kira J
Mult Scler; 2009 Dec; 15(12):1411-21. PubMed ID: 19965522
[TBL] [Abstract][Full Text] [Related]
11. Chlamydia pneumoniae seropositivity in Iranian patients with multiple sclerosis: a pilot study.
Aghaei M; Ashtari F; Bahar M; Falahian MR
Neurol Neurochir Pol; 2011; 45(2):128-31. PubMed ID: 21574116
[TBL] [Abstract][Full Text] [Related]
12. Impact of Helicobacter pylori on multiple sclerosis-related clinically isolated syndrome.
Deretzi G; Gavalas E; Boziki M; Tsiptsios D; Polyzos SA; Venizelos I; Zavos C; Koutlas E; Tsiptsios I; Katsinelos P; Kountouras J
Acta Neurol Scand; 2016 Apr; 133(4):268-75. PubMed ID: 26079721
[TBL] [Abstract][Full Text] [Related]
13. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
[TBL] [Abstract][Full Text] [Related]
15. Relationship between
Gavalas E; Kountouras J; Boziki M; Zavos C; Polyzos SA; Vlachaki E; Venizelos I; Tsiptsios D; Deretzi G
Ann Gastroenterol; 2015; 28(3):353-356. PubMed ID: 26126617
[TBL] [Abstract][Full Text] [Related]
16. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
Ziemssen T; Piani-Meier D; Bennett B; Johnson C; Tinsley K; Trigg A; Hach T; Dahlke F; Tomic D; Tolley C; Freedman MS
J Med Internet Res; 2020 Feb; 22(2):e16932. PubMed ID: 32049062
[TBL] [Abstract][Full Text] [Related]
17. Deep gray matter volume loss drives disability worsening in multiple sclerosis.
Eshaghi A; Prados F; Brownlee WJ; Altmann DR; Tur C; Cardoso MJ; De Angelis F; van de Pavert SH; Cawley N; De Stefano N; Stromillo ML; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Vrenken H; Leurs CE; Killestein J; Pirpamer L; Enzinger C; Ourselin S; Wheeler-Kingshott CAMG; Chard D; Thompson AJ; Alexander DC; Barkhof F; Ciccarelli O;
Ann Neurol; 2018 Feb; 83(2):210-222. PubMed ID: 29331092
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
[TBL] [Abstract][Full Text] [Related]
19. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
20. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
